Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

Phase 2

Completed

Conditions: Cushing Disease

Interventions: Drug: Pasireotide

Registration Number: NCT00171951

Lead Sponsor: Novartis Pharmaceuticals

Brief Summary: Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study assessed the long-term safety and efficacy of pasireotide in participants with Cushing's disease.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 19

Inclusion Criteria

Participants who have completed the 15 days of Pasireotide treatment in the CSOM230B2208 study and have achieved normalization of 24-hour urinary free cortisol. Participants who did not achieve normalization of 24 -hour urinary free cortisol may be enrolled if in the opinion of the investigator the participant is getting significant clinical benefits from treatment with Pasireotide .
The participant did not experience any unacceptable adverse events of tolerability issues during the original 15 day treatment.
Female participants of childbearing potential who have not undergone clinically documented total hysterectomy and/or ovariectomy or tubal ligation must agree to use barrier contraception throughout the course of the extension study, and for one month after the study has ended.

Exclusion Criteria

Participant who have developed poorly controlled diabetes mellitus as indicated by ketoacidosis or hemoglobin (Hgb) A1C (HgbA1C) > 10 since starting [study CSOM230B2208].
Participant with persistent alanine aminotransferase (ALT)/ aspartate transaminase (AST) or alkaline phosphatase levels more than 2.5X upper limit of normal (ULN), serum creatinine > 2.0 X ULN, serum bilirubin > 2 X ULN.
Participant with abnormal coagulation (Prothrombin time (PT) and partial thromboplastin time (PTT) elevated by 30% above normal limits), white blood cells (WBC) <3.0x1'000'000'000/L; Hgb <12.0g/dL for females, Hgb <13.0g/dL for males; PLT <100x1'000'000'000/L.

Other protocol-defined inclusion / exclusion criteria may apply.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Pasireotide 600 μg BID SC or Ramp up Dose 900 μg BID SC	Pasireotide	Participants received pasireotide 600 micrograms (μg) twice daily (BID) subcutaneously (SC) to achieve or maintain urinary free cortisol (UFC) normalization. If UFC levels were increased at any time, participants received 900 μg BID SC, until no safety or tolerability concerns were observed as per investigators assessment. If the participant was unable to tolerate the 900 μg BID, dosing of 600 μg three times a day was given.

Primary Outcome Measures

Name	Time	Method
Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits	Month 6	A participant was considered a responder if the mean UFC from the two 24-hour urine samples collected at Month 6 was within normal limits. The normal range for UFC is 55 to 276 nmol/day.
Change From Baseline in Mean Urinary Free Cortisol (UFC)	Core Baseline, Days 14/15 (Core study), Months 6, 12, 24 and 102	24-hour urine samples were collected to obtain mean UFC measurements. A negative mean change from baseline indicates improvement.

Secondary Outcome Measures

Name	Time	Method
Plasma Trough Concentrations (Ctrough) of Pasireotide in UFC Responders	Day 15 (Core study) and Month 6	Participants with Cushing's disease were considered responders if mean UFC levels from the 24-hour urine collections at Day 15 (Core study) and at extension Month 6, were within normal limits. Ctrough levels of pasireotide were measured at Day 15 of Core study and Month 6.
Change From Baseline in Gene-expression and Protein in Blood and Urine for Biomarker Development	Baseline to end of the study
Change From Baseline in Serum Cortisol Levels	Core Baseline, Day 15 (Core study), Months 6, 12, 24, and Month 105 (end of the study)	Blood samples were withdrawn to obtain the serum cortisol levels. A negative change from baseline indicates improvement.
Number of Participants Who Had At Least One Adverse Event (AE)	Up to approximately 106 months	An AE was any undesirable sign, symptom or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. AEs were assessed according to incident dose group: Pasireotide 1200 μg sc total daily dose (TDD), Pasireotide 1800 μg SC TDD and Pasireotide SC Any Dose. The incident dose for an AE was the last total daily dose administered on or prior to the AE onset date.
Change From Baseline in Plasma Adrenocorticotropic Hormone (ACTH) Levels	Core Baseline, Day 15 (Core study), Months 6, 12, 24 and Month 105 (end of the study)	Blood samples were withdrawn to obtain the ACTH levels. A negative change from baseline indicates improvement.

Trial Locations

Locations (4): Novartis Investigative Site
🇬🇧
Belfast, United Kingdom
Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU.
🇺🇸
Portland, Oregon, United States
Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
University of Pennsylvania Medical Center
🇺🇸
Philadelphia, Pennsylvania, United States